Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Malaria, a disease caused by the parasite Plasmodium, is one of the world's major infectious
diseases. With approximately 627.000 deaths a year, there is desperate need for an effective
vaccine. Though a number of vaccine-candidates have been developed, they have yet to achieve
the level of efficacy necessary to eliminate malaria. It has been shown previously that
healthy human volunteers bitten by malaria-infected mosquitoes while taking chloroquine,
medicine that prevents malaria, are fully protected against a subsequent malaria challenge.
This is called CPS-immunization. The unprecedented effectiveness of CPS-immunization makes it
a good model to identify what immune responses protect against malaria, to further guide
vaccine development. In this study we will use CPS-immunization to induce protection against
malaria in healthy subjects and then analyse their immune response to a malaria challenge
infection.
Phase:
N/A
Details
Lead Sponsor:
Radboud University
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Atovaquone Atovaquone, proguanil drug combination Chloroquine Chloroquine diphosphate Proguanil Vaccines